Manuela Zereu

Learn More
BACKGROUND This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC)(More)
BACKGROUND Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed(More)
5048 Background: Cervical cancer is an important public health problem worldwide. Following skin and breast carcinoma, cervical cancer is the third most common cancer among Brazilian women, ranking(More)
  • 1